The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Drug repurposing screens and synergistic drug‐combinations for infectious diseases
Open accessAbstract
Infectious diseases account for nearly one fifth of the worldwide death toll every year. The continuous increase of drug‐resistant pathogens is a big challenge for treatment of infectious diseases. In addition, outbreaks of infections and new pathogens are potential threats to public health. Lack of effective treatments for drug‐resistant bacteria and recent outbreaks of Ebola and Zika viral infections have become a global public health concern. The number of newly approved antibiotics has decreased significantly in the last two decades compared with previous decades. In parallel with this, is an increase in the number of drug‐resistant bacteria. For these threats and challenges to be countered, new strategies and technology platforms are critically needed. Drug repurposing has emerged as an alternative approach for rapid identification of effective therapeutics to treat the infectious diseases. For treatment of severe infections, synergistic drug combinations using approved drugs identified from drug repurposing screens is a useful option which may overcome the problem of weak activity of individual drugs. Collaborative efforts including government, academic researchers and private drug industry can facilitate the translational research to produce more effective new therapeutic agents such as narrow spectrum antibiotics against drug‐resistant bacteria for these global challenges. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The complete genome sequence of the gram-positive bacterium Bacillus subtilis.
Kunst, F., Ogasawara, N., Moszer, I., Albertini, A. M., Alloni, G., Azevedo, V., Bertero, M. G., Bessières, P., Bolotin, A., Borchert, S., et al. (1997) · Nature · doi:10.1038/36786 · Cited by 3,679
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
Snitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863
Zika virus and microcephaly: why is this situation a PHEIC?
Heymann, D. L., Hodgson, A., Sall, A. A., Freedman, D. O., Staples, J. E., Althabe, F., Baruah, K., Mahmud, G., Kandun, N., Vasconcelos, P. F. C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00320-2 · Cited by 415
Cited by
Network-based prediction of drug combinations
Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019) · Nature Communications · doi:10.1038/s41467-019-09186-x · Cited by 800
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Discovery and development of safe-in-man broad-spectrum antiviral agents
Andersen, P. I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjørås, M., Telling, K., Lutsar, I., Dumpis, U., Irie, Y., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.018 · Cited by 280
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264
DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
Wang, J., Liu, X., Shen, S., Deng, L., & Liu, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab390 · Cited by 261
Metadata
- Authors
- Zheng, W., Sun, W., & Simeonov, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-07-09
- Volume
- 175
- Issue
- 2
- Pages
- 181-191
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2724799126
- Cited by
- 247
- References
- 5
- FWCI
- 16.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug repurposing screens and synergistic drug‐combinations for infectious diseases. https://app.cochat.ai/papers/10.1111/bph.13895
- The paper
- Zheng, W., Sun, W., & Simeonov, A. (2018). Drug repurposing screens and synergistic drug‐combinations for infectious diseases. British Journal of Pharmacology. https://doi.org/10.1111/bph.13895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.